Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksSTU:2Q5 26 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 376 Biotechnology companies, Lunai Bioworks ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lunai Bioworks's
Operating Income
for the
three
months ended in Mar. 2026 was €-1.23 Mil. Lunai Bioworks's Interest Expense for the
three
months ended in Mar. 2026 was €-0.11 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Lunai Bioworks's Interest Coverage or its related term are showing as below:
STU:2Q5's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.135 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lunai Bioworks Interest Coverage Related Terms
Lunai Bioworks Interest Coverage Historical Data
* Premium members only.
The historical data trend for Lunai Bioworks's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:2Q5 vs BCLI, BIVI, XCUR: Interest Coverage Comparison
For the Biotechnology subindustry, Lunai Bioworks's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Lunai Bioworks did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Lunai Bioworks (STU:2Q5) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #999999 out of 376 companies in the Biotechnology industry.
Is Lunai Bioworks' Interest Coverage too high?
Lunai Bioworks' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Lunai Bioworks ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Interest Coverage compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #999999 out of 376 companies for Interest Coverage. This places Lunai Bioworks in the lower half of its industry. The industry median Interest Coverage is 106.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score
Get the complete analysis for STU:2Q5
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Q5 has been successfully added to your 
